|Year : 2021 | Volume
| Issue : 3 | Page : 117-121
The rs4808793 polymorphism of GDF-15 associates with significantly elevated ferritin in both thalassemia major and thalassemia intermedia
Reza Atar1, Dian Dayer2, Mohammad Ali Jalalifar1, Bijan Keikhaei3, Zari Tahan Nejad Asadi1
1 Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health; Department of Laboratory Sciences, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
|Date of Submission||14-Dec-2020|
|Date of Decision||23-Jan-2021|
|Date of Acceptance||01-Mar-2021|
|Date of Web Publication||21-Jul-2021|
Zari Tahan Nejad Asadi
Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz
Source of Support: None, Conflict of Interest: None
Background: Previous studies have proposed the rs4808793 polymorphism of the GDF-15 as a potent inducer of hypertension, cardiovascular disease, and renal failure. The current study was performed to investigate the role of rs4808793 polymorphism in the pathogenesis of iron overload in patients suffering from major or intermedia β-thalassemia. Materials and Methods: The study included 69 major thalassemia patients and 25 intermedia thalassemia patients as the control group. The study was conducted on 69 major thalassemia and 25 intermedia thalassemia patients who referred to Baqa'i Hospital 2 in Ahvaz, Iran. Five milliliter blood was collected and DNA was extracted. After DNA amplification by the use of polymerase chain reaction, the rs4808793 polymorphism was detected by AlwNI restriction enzyme application and restriction fragment length polymorphism. Results: Mean serum ferritin in patients with β-thalassemia major (3490.41 ± 169.22 ng/ml) was significantly higher than those with thalassemia intermedia (677.16 ± 388.80) (P < 0.05). The frequency of mutation showed no statistically significant difference between cases and controls (41% vs. 32%) (P > 0.05). Both cases and controls with rs4808793 polymorphism showed significantly elevated serum ferritin concentrations compared to patients without mutations (P < 0.05). Conclusion: Incidence of rs4808793 GDF-15 polymorphism can be considered as an effective factor in iron overload, exposing people to thalassemia, both in thalassemia major and intermediate groups.
Keywords: Ferritin, GDF-15, rs4808793 polymorphism, β-thalassemia intermedia, β-thalassemia major
|How to cite this article:|
Atar R, Dayer D, Jalalifar MA, Keikhaei B, Asadi ZT. The rs4808793 polymorphism of GDF-15 associates with significantly elevated ferritin in both thalassemia major and thalassemia intermedia. Clin Cancer Investig J 2021;10:117-21
|How to cite this URL:|
Atar R, Dayer D, Jalalifar MA, Keikhaei B, Asadi ZT. The rs4808793 polymorphism of GDF-15 associates with significantly elevated ferritin in both thalassemia major and thalassemia intermedia. Clin Cancer Investig J [serial online] 2021 [cited 2021 Aug 2];10:117-21. Available from: https://www.ccij-online.org/text.asp?2021/10/3/117/322059
| Introduction|| |
Iron overload can be considered as one of the major problems in patients with β-thalassemia. Iron accumulation in the cell induces reactive oxygen species production, apoptosis, necrosis, and inflammation. The other complications include heart damage, liver damage, liver cirrhosis, pancreatic islet cell damage, diabetes, hypothyroidism, and hypogonadism., Currently, much research is being done to reduce the problem of iron overload in β-thalassemic patients. Some research studies have suggested GDF-15 overexpression as a trigger for iron overload. GDF-15 is an inflammatory cytokine that belongs to the transforming growth factor-β superfamily. The GDF-15 is expressed in most tissues. However, mature hemoglobin-containing erythroblasts, prostate, and placenta show the maximum values of expression. Previous studies have shown significant elevations of GDF-15 expression in patients suffering from prostate cancer, cardiovascular disease, type 2 diabetes mellitus, and β-thalassemia., The elevated levels of GDF-15 in β-thalassemia can be justified by an unusual proliferation of erythroid cells and ineffective erythropoiesis. Recent studies have demonstrated that GDF-15 serum concentrations above 10,000 pg/ml inhibit hepcidin expression in β-thalassemia patients. GDF-15 overexpression causes decreased expression of hepcidin that ultimately results in iron overload. Some surveys have proposed a probable role of GDF-15 polymorphisms in altering iron homeostasis. The rs4808793 polymorphism of GDF-15 results from the replacement of G allele instead of C allele in the upstream region of GDF-15. The study conducted by Athiyarath et al. revealed that among eight different polymorphisms of GDF-15, the rs4808793 polymorphism was associated with significant elevation in GDF-15 expression. The results of this study showed a significant reverse association between GDF-15 expression and hepcidin levels. However, no significant change in Ferritin concentration was noticed. In another study, a significant positive correlation between GDF-15 concentrations and ferritin levels in transfusion-dependent β-thalassemia patients with Iron overload was reported. Due to the remarkable increase of GDF-15 expression in β-thalassemia patients and its inhibitory effect on hepcidin expression, the genetic variations in GDF-15 may influence the Iron overload condition in β-thalassemia patients. In this regard, the study of iron deposition statue in β-thalassemia patients with genetic variations in GDF-15 may be a useful approach to ameliorate iron overloading. Here, we investigated the prevalence of the rs4808793 polymorphism of GDF-15 and the association of this polymorphism with iron overload in patients with β-thalassemia major compared to patients with intermediate thalassemia.
| Materials and Methods|| |
This study was approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences (IR.AJUMS.REC.1397.940). A case–control study was conducted. The study was conducted in accordance with ethical procedures and policies approved by the Ethical Committee of Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran, and Helsinki Declaration of 1975. The study group was selected from the patients suffering from major or intermedia thalassemia who were referred to Baqa'i Hospital 2 in Ahvaz, Iran. The patients' incidence of thalassemia was previously confirmed by specialists with regard to medical examinations and blood experiments. Patients with similar hemoglobinopathies such as sickle cell anemia were excluded from the study. The study was conducted on 69 patients with major thalassemia as a case group and 25 patients with intermedia thalassemia as a control group.
Blood samples preparation method
Informed consent was obtained from all patients and controls. Five milliliter of peripheral blood was collected in the tubes that contained ethylenediaminetetra acetic acid.
DNA was extracted using the Yekta Tajhiz Azma (IRAN) kit according to the manufacturer's instructions. The DNA concentration was determined at the wavelength of 260 nm using a NanoDrop spectrophotometer (NanoDrop 2000™; Thermo Fisher Scientific, Waltham, MA, USA). The unimpaired DNA was confirmed by OD 260/280 nm between 1.8 and 2. The extracted DNAs were labeled and stored at −20°C until use.
Polymerase chain reaction
Polymerase chain reaction (PCR) was carried out in the total volume of 25 μL using Taq DNA Polymerase × 2 Master Mix RED (Ampliqon, Odense, Denmark). The specific primers (Bioneer Corporation) used for the amplification of full-length GDF-15 gene included 5'-GCAACAGAGCGAGACTCCA-3' and 5'-CCACGCCGGTCGGATTAAAACT-3'. The primers were designed using primer premier 5.0 software (Premier Biosoft, Palo Alto, CA, USA). The accuracy of primers was confirmed using Bioinformatics org/sms2/primer stats online software. The PCR was carried out using a thermal cycler (Eppendorf Mastercycler International, Hamburg, Germany). The thermal program given consisted of 40 cycles as follows: initial denaturation at 95°C for 5 min, denaturation at 94°C for 1 min, annealing at 60°C for 1 min, extension at 72°C for 1 min, and a final extension at 72°C for 10 min. The PCR products were transferred on 1% agarose gel stained by Safe stain (SinaClon BioSciences) and subjected to electrophoresis at 100V for 40 min then visualized using a Vilber Lourmat (France) transilluminator.
The proper restriction enzyme (AlwNI) (Thermo, USA) was chosen by the use of NEB Cutter online software. The intact PCR products were subjected to enzymatic restriction as follows: 5 μl of PCR product was mixed with 1 μl AlwNI enzyme, 1 μl of enzymatic buffer, and 8 μl of deionized water and incubated at 37°C for 2 h. The products were quantified versus a 100 bp DNA ladder on 1% agarose gel.
For final confirmation of enzymatic digestion results, a number of 10 AlwNI digested DNAs (5 mutated DNAs and 5 wild DNAs) were sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit in an ABI 3130 Genetic Analyzer (Applied Biosystems, Waltham, MA, USA).
The quantitative data normality was assessed using the Kolmogorov–Smirnov test. Evaluation of the relationship between quantitative variables was carried out using an independent t-test. The relationship between two qualitative variables was examined by the Chi-square test. The significance level was considered <0.05. Data analysis was performed using USA, Microsoft company. 22 software.
| Results|| |
The present study was performed on 69 individuals with thalassemia major and 25 individuals with intermediate thalassemia. In total, 43 subjects were female (45.7%) and 51 were male (54.3%). In the group with thalassemia major, the mean age was calculated as 26 ± 9.11 years and the mean age of control group was 24.36 ± 9.64 years. The mean age showed no statistically significant difference between cases and controls (P > 0.05).
Polymerase chain reaction results
In accordance with GDF-15 expression, all samples showed a single clear band on 665 bp region [Figure 1].
|Figure 1: Polymerase chain reaction products on agarose gel. A clear single band on 665 bp region was yielded|
Click here to view
Enzyme digestion results
After enzymatic cleavage, the samples were visible on agarose gel in two ways: (1) nonmutant samples that lacked enzymatic cleavage and had a single band in the 665 bp region and (2) mutant samples that had an enzymatic section and showed two bands on the gel, one in the 243 bp region and the other in the 422 bp region [Figure 2].
|Figure 2: Bands created after enzymatic cleavage. The wild samples showed an intact band on 665 region, but the mutants showed two distinct bands on 243 bp and 422 bp regions|
Click here to view
Prevalence of rs4808793 polymorphism
In total, 38% of the total population showed G/C mutations. The frequency of rs4808793 polymorphism was 41% in patients with thalassemia major and 32% in patients with thalassemia intermedia. The frequency of mutations between the two groups did not show a statistically significant difference (P > 0.05) [Table 1].
Comparison of ferritin levels in the two groups
Mean serum ferritin in patients with β-thalassemia major was 3490.41 ± 169.22 ng/ml, which was significantly higher than those with thalassemia intermedia (677.16 ± 388.80) (P < 0.05).
Relationship between the prevalence of polymorphism and serum ferritin
Data analysis showed that in both the group of patients with β-thalassemia major and in the control group, the level of serum ferritin in people with polymorphism was significantly higher than those without mutations (P < 0.05).
| Discussion|| |
Today, the iron overload is the most important risk factor for patients with thalassemia, which puts patients at high risk for chronic liver failure, heart disease, thyroid hormone disorders, sex hormones disturbances, infections, osteoporosis, and spleen damages., Therefore, researchers are trying to identify the factors affecting iron overload and prevent the accumulation of harmful iron accumulation in tissues. Blood transfusions are the most important cause of iron overload., Due to the fact that patients' red blood cells lack the proper function to deliver oxygen to the body's tissues, patients need regular blood transfusions. Although blood transfusions have largely prevented the progression of the disease and improved the clinical condition of patients, regular transfusions have a number of side effects for patients. In 2020, Advani et al. conducted a study to evaluate iron overload on cardiac function in patients with thalassemia major. Their results showed that iron overload leads to increased QT time and impaired echocardiogram. Therefore, they concluded that assessing heart function using echocardiograms could be a diagnostic tool in people at high risk for iron overload. Another study by Çetinçakmak et al. to evaluate iron overload on endocrine organs showed that spleen resection in thalassemia patients resulted in iron accumulation in the heart and liver and reduced survival. The GDF-15 is known to play an important role in the regulation of iron metabolism in the body. GDF-15 plays an important role in regulating hepcidin expression by preventing its expression. Hepcidin in normal condition prevents the absorption of iron by cells and thus prevents the accumulation of iron in the heart and liver. Thus, GDF-15 overexpression results in iron overload through hepcidin downregulation. According to previous studies, mutations in the gene encoding GDF-15 in patients with thalassemia major increase its expression in patients, so mutations in the GDF-15 gene may possibly increase iron overload and intensify the thalassemia complications., In this study, we performed a study on patients with thalassemia major and intermedia to evaluate the incidence of GDF-15 polymorphism. Intermediate thalassemia has less clinical severity than thalassemia major. Patients with thalassemia intermedia despite the reduced symptoms of the disease and less blood transfusion requirement show some symptoms of the iron overload. Therefore, in this study, the frequency of rs4808793 GDF-15 gene polymorphism in patients with thalassemia major and intermedia was compared. The results showed that the prevalence of polymorphism in thalassemia major patients was 41% versus 32% in intermediate thalassemia patients. This difference was not statistically significant. Therefore, the incidence of rs4808793 polymorphism may be regarded as one of the predisposing factors for developing thalassemia. The present results showed that the amount of ferritin in patients with thalassemia major was higher than patients with thalassemia intermedia and the difference was statistically significant. This result confirmed the increased chance of developing iron overload in people with thalassemia major compared to people with intermediate thalassemia. In addition, the present study showed that in both the groups with thalassemia major and intermedia, the level of serum ferritin in people with polymorphism is significantly higher than those without mutations. Therefore, the incidence of rs4808793 polymorphism in both the groups can be considered as a predisposing factor for iron overload. Similarly, in a study conducted by Athiyarath et al. to evaluate the rs4808793 polymorphism association with ferritin levels in patients with thalassemia major, the results showed that the presence of G allele in this polymorphism was associated with a significant increase in GDF-15 levels in patients and significantly decreased hepcidin levels in major thalassemic patients compared with normal control subjects. However, no statistically significant difference in ferritin levels was noticed between the patients and controls. The study conducted by Tantawy et al. showed that increased ferritin levels in thalassemia patients were associated with cardiovascular disorders (CVD). In the study conducted by Zhou et al., patients with CVD showed significant elevated levels of GDF-15. Another study by Sayani et al. showed that in patients with thalassemia major, increased GDF-15 expression was associated with increased ferritin and iron overload in the liver and heart, which ultimately led to the dysfunction of both organs and endocrine disorders. The study conducted by Li et al. in dialysis patients showed no significant association between GDF-15 expression levels and ferritin.
| Conclusion|| |
It is concluded that the incidence of rs4808793 polymorphism in the gene encoding GDF-15 could be regarded as one of the predisposing factors to thalassemia. Considering that in this study, in both the groups with thalassemia major and intermedia, the incidence of rs4808793 polymorphism was significantly associated with serum ferritin concentration; it can be concluded that the presence of rs4808793 polymorphism has a chance of iron overload and increases incidence-related disorders in patients with thalassemia. However, further studies are needed in this issue.
We wish to thank all our colleagues in Golestan Hospital and Allied Health Sciences School, Ahvaz Jundishapur University of Medical Sciences.
Financial support and sponsorship
This work was financially supported by a grant (Th-9722) from vice chancellor for research affairs of the Ahvaz Jundishapur University of Medical Sciences.
Conflicts of interest
There are no conflicts of interest.
| References|| |
Prabhu R, Prabhu V, Prabhu R. Iron overload in beta thalassemia: A review. J Biosci Tech 2009;1:20-31.
Koohi F, Kazemi T, Miri-Moghaddam E. Cardiac complications and iron overload in beta thalassemia major patients – A systematic review and meta-analysis. Ann Hematol 2019;98:1323-31.
Haybar H, Shahrabi S, Rezaeeyan H, Jodat H, Saki N. Strategies to inhibit arsenic trioxide-induced cardiotoxicity in acute promyelocytic leukemia. J Cell Physiol 2019;234:14500-6.
Tantawy AA, Adly AA, Ismail EA, Darwish YW, Ali Zedan M. Growth differentiation factor-15 in young sickle cell disease patients: Relation to hemolysis, iron overload and vascular complications. Blood Cells Mol Dis 2014;53:189-93.
Tanno T, Noel P, Miller JL. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol 2010;17:184-90.
Nair V, Robinson-Cohen C, Smith MR, Bellovich KA, Bhat ZY, Bobadilla M, et al
. Growth differentiation factor-15 and risk of CKD progression. J Am Soc Nephrol 2017;28:2233-40.
Haybar H, Shahrabi S, Rezaeeyan H, Shirzad R, Saki N. Protective role of heat shock transcription factor 1 in heart failure: A diagnostic approach. J Cell Physiol 2019;234:7764-70.
Theurl I, Finkenstedt A, Schroll A, Nairz M, Sonnweber T, Bellmann-Weiler R, et al
. Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Br J Haematol 2010;148:449-55.
Athiyarath R, George B, Mathews V, Srivastava A, Edison ES. Association of growth differentiation factor 15 (GDF15) polymorphisms with serum GDF15 and ferritin levels in β-thalassemia. Ann Hematol 2014;93:2093-5.
Musallam KM, Sankaran VG, Cappellini MD, Duca L, Nathan DG, Taher AT. Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. Blood 2012;119:364-7.
Motta I, Mancarella M, Marcon A, Vicenzi M, Cappellini MD. Management of age-associated medical complications in patients with β-thalassemia. Expert Rev Hematol 2020;13:85-94.
Saki N, Abroun S, Salari F, Rahim F, Shahjahani M, Javad MA. Molecular aspects of bone resorption in β-thalassemia major. Cell Journal (Yakhteh) 2015;17:193.
Shaykhbaygloo R, Moradabadi A, Taherahmadi H, Rafiei M, Lotfi F, Eghbali A. Correlation of cardiac and liver iron level with T2* MRI and vitamin D3 serum level in patients with thalassemia major. J Blood Med 2020;11:83.
Saki N, Abroun S, Soleimani M, Kavianpour M, Shahjahani M, Mohammadi-Asl J, et al
. MicroRNA expression in β-thalassemia and sickle cell disease: A role in the induction of fetal hemoglobin. Cell J (Yakhteh) 2016;17:583.
Karimi M, Nikrooz P, Kashef S, Jamalian N, Davatolhagh Z. RBC alloimmunization in blood transfusion-dependent β-thalassemia patients in southern Iran. Int J Lab Hematol 2007;29:321-6.
Advani N, Kautsar A, Andriastuti M. The corrected QT interval prolongation in adolescents with cardiac iron overload β-thalassemia major. Turk J Pediatr 2020;62:267-73.
Çetinçakmak MG, Hattapoğlu S, Söker M, Ekici F, Yilmaz K, Göya C, et al
. Evaluation of the relationship between splenic iron overload and liver, heart and muscle features evident on T2*-weighted magnetic resonance imaging. Adv Clin Exp Med 2020;29:475-80.
Nalado AM, Olorunfemi G, Dix-Peek T, Dickens C, Khambule L, Snyman T, et al
. Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa. BMC Nephrol 2020;21:1-0.
Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006;26:323-42.
Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al
. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007;13:1096-101.
Atichartakarn V, Chuncharunee S, Chandanamattha P, Likittanasombat K, Aryurachai K. Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E/β-thalassemia patient. Blood 2004;103:2844-6.
Tantawy AA, Adly AA, Ismail EA, Youssef OI, Ali ME. Growth differentiation factor-15 in children and adolescents with thalassemia intermedia: Relation to subclinical atherosclerosis and pulmonary vasculopathy. Blood Cells Mol Dis 2015;55:144-50.
Zhou YM, Li MJ, Zhou YL, Ma LL, Yi X. Growth differentiation factor-15 (GDF-15), novel biomarker for assessing atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease. Int J Clin Exp Med. 2015;8:21201-7.
Sayani, Farzana, Sukhvinder Bansal, Patricia Evans, Aalim Weljie, Robert C. Hider, and John B. Porter. “Disease Specific Modulation of Serum Hepcidin: Impact of GDF-15 and Iron Metabolism Markers in Thalassemia Major, Thalassemia Intermedia and Sickle Cell Disease: A Univariate and Multivariate Analysis.” (2008): 3850-3850.
Li XY, Ying J, Li JH, Zhu SL, Li J, Pai P. Growth differentiation factor GDF-15 does not influence iron metabolism in stable chronic haemodialysis patients. Ann Clin Biochem 2015;52:399-403.
[Figure 1], [Figure 2]